Abrupt respiratory insufficiency presenting initially as myasthenia gravis crisis with thymic carcinoma - a case report

Abstract

Myasthenia gravis (MG) is frequently complicated by respiratory insufficiency, which is known as an MG crisis. It can appear as the initial presenting symptom of myositis-MG overlap. Here we report a case of a 67-year-old woman with previously underdiagnosed MG, who presented with acute respiratory insufficiency. A bulky mass in the right lung was pathologically suspected to be a lymphoepithelioma-like carcinoma of the thymus. Due to high expression of programmed death-ligand 1 (PD-L1) (70%-80%) on the tumor, the immune checkpoint inhibitor (ICI) pembrolizumab was administered as second-line therapy. However, the patient died of ICI-induced myocarditis, which was confirmed by autopsy. Immunohistochemistry showed an overexpression of PD-L1 on the myocardial sarcolemma as well as the diaphragm. PD-L1 overexpression on the diaphragm might have contributed to the pathogenesis of myositis-MG overlap with acute respiratory insufficiency.

Keywords

Crisis / Myasthenia gravis / Respiratory insufficiency / Thymic carcinoma

ACKNOWLEDGEMENTS

We thank Masaru Kobayaka for assisting preparation of biopsy and autopsy samples as a laboratory technician.

CONFLICTS OF INTEREST DISCLOSURE

There is no conflict of interest.

References

[1] Lacomis D. Myasthenic crisis. Neurocrit Care. 2005; 3: 189-194. https://doi.org/10.1385/NCC:3:3:189

[2] Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011; 1: 16-22. PMid:23983833. https://doi.org/10.1177/1941875210382918

[3] Gracey DR, Divertie MB, Howard FM Jr. Mechanical ventilation for respiratory failure in myasthenia gravis. Two-year experience with 22 patients. Mayo Clin Proc. 1983; 58: 597-602.

[4] Lee SJ, Hur J, Lee TW, et al. Myasthenia gravis presenting initially as acute respiratory failure. Respir Care. 2015; 60: e14-e16. PMid:25185150. https://doi.org/10.4187/respcare.03210

[5] Uchio N, Taira K, Ikenaga C, et al. Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology. Neurol Neuroimmunol Neuroinflamm. 2019; 6: e535. PMid:30697585. https://doi.org/10.1212/NXI.0000000000000535

[6] Kurihara N, Saito H, Nanjo H, et al. Thymic carcinoma with myasthenia gravis: Two case reports. Int J Surg Case Rep. 2016; 27: 110-112. PMid:27591911. https://doi.org/10.1016/j.ijscr.2016.08.010

[7] Lemma GL, Lee J-W, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011; 29: 2060-2065. PMid:21502559. https://doi.org/10.1200/JCO.2010.32.9607

[8] Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol. 2019; 37: 2162-2170. PMid:29906252. https://doi.org/10.1200/JCO.2017.77.3184

[9] Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018; 19: 347-355. https://doi.org/0.1016/S1470-2045(18)30062-7

[10] Fregonezi GA, Resqueti VR, Guell R, et al. Effects of 8-week, interval-based inspiratory muscle training and breathing retraining in patients with generalized myasthenia gravis. Chest. 2005; 128: 1524-1530. PMid:16162753. https://doi.org/10.1378/chest.128.3.1524

[11] Paik JJ, Corse AM, Mammen AL. The co-existence of myasthenia gravis in patients with myositis: A case series. Semin Arthritis Rheum. 2014; 43(6): 792-796. PMid: 24412588. https://doi.org/10.1016/j.semarthrit.2013.12.005

[12] Garibaldi M, Fionda L, Vanoli F, et al. Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of myastheniamyositis association from a large cohort of patients. Autoimmun Rev. 2020; 19: 102498. PMid:32062029. https://doi.org:10.1016/j.autrev.2020.102498

[13] Suster D, Pihan G, Mackinnon AC, et al. Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus. Mod Pathol. 2018; 31: 1801-1806. PMid:29973653. https://doi.org/10.1038/s41379-018-0097-4

[14] Helgeland G, Luckman SP, Romi FR, et al. Myasthenia gravis sera have no effect on cardiomyocytes in vitro. J Neuroimmunol. 2008; 201: 74-79. PMid:18632164. https://doi.org/10.1016/j.jneuroim.2008.05.021

[15] Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol. 2009; 66: 1334-1338. PMid:19752287. https://doi.org/10.1001/archneurol.2009.229

[16] Iwasa K, Yoshikawa H, Furukawa Y, et al. Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis. J Neuroimmunol. 2018; 325: 74-78. PMid:30278997. https://doi.org/10.1016/j.jneuroim.2018.09.012

[17] Mammen AL, Rajan A, Pak K, et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis. 2019; 78: 150-152. PMid:30185415. https://doi.org/10.1136/annrheumdis-2018-213777

[18] Zhang S, Wang L, Li M, et al. The PD-1/PD-L pathway in rheumatic diseases. J Formos Med Assoc. 2021; 120(1 Pt 1): 48-59. PMid:32334916. https://doi.org/10.1016/j.jfma.2020.04.004